DK0804584T3 - Sekvenser af hepatitis C virus genotype 7 og deres anvendelse som profylaktiske, terapeutiske og diagnostiske midler - Google Patents

Sekvenser af hepatitis C virus genotype 7 og deres anvendelse som profylaktiske, terapeutiske og diagnostiske midler

Info

Publication number
DK0804584T3
DK0804584T3 DK95936537T DK95936537T DK0804584T3 DK 0804584 T3 DK0804584 T3 DK 0804584T3 DK 95936537 T DK95936537 T DK 95936537T DK 95936537 T DK95936537 T DK 95936537T DK 0804584 T3 DK0804584 T3 DK 0804584T3
Authority
DK
Denmark
Prior art keywords
sequences
prophylactic
therapeutic
hepatitis
diagnostic agents
Prior art date
Application number
DK95936537T
Other languages
English (en)
Inventor
Geert Maertens
Lieven Stuyver
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26137782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0804584(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Application granted granted Critical
Publication of DK0804584T3 publication Critical patent/DK0804584T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK95936537T 1994-10-21 1995-10-23 Sekvenser af hepatitis C virus genotype 7 og deres anvendelse som profylaktiske, terapeutiske og diagnostiske midler DK0804584T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94870166 1994-10-21
EP95870076 1995-06-28
PCT/EP1995/004155 WO1996013590A2 (en) 1994-10-21 1995-10-23 New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents

Publications (1)

Publication Number Publication Date
DK0804584T3 true DK0804584T3 (da) 2002-09-23

Family

ID=26137782

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95936537T DK0804584T3 (da) 1994-10-21 1995-10-23 Sekvenser af hepatitis C virus genotype 7 og deres anvendelse som profylaktiske, terapeutiske og diagnostiske midler

Country Status (12)

Country Link
US (2) US7129337B1 (da)
EP (2) EP1076092A3 (da)
JP (2) JPH10507643A (da)
AT (1) ATE218617T1 (da)
AU (1) AU702436B2 (da)
BR (1) BR9509421A (da)
CA (1) CA2201703A1 (da)
DE (1) DE69526973T3 (da)
DK (1) DK0804584T3 (da)
ES (1) ES2176342T5 (da)
PT (1) PT804584E (da)
WO (1) WO1996013590A2 (da)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9620075D0 (en) * 1996-09-26 1996-11-13 Dynal As Method
US7078500B1 (en) * 1998-01-30 2006-07-18 The General Hospital Corporation Genetic immunization with nonstructural proteins of hepatitis C virus
TR200003024T2 (tr) 1998-04-17 2000-12-21 Innogenetics N.V. İndirgeme ajanlarını kullanarak geliştirilen immünodiagnostik tahliller.
AU4497999A (en) * 1998-04-28 1999-11-16 Ingrid-Corina Bergter Radioimmunopharmaca for treating hepatitis c
WO1999067285A1 (en) * 1998-06-24 1999-12-29 Innogenetics N.V. Particles of hcv envelope proteins: use for vaccination
US6680059B2 (en) * 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6858590B2 (en) * 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6960569B2 (en) * 2000-08-17 2005-11-01 Tripep Ab Hepatitis C virus non-structural NS3/4A fusion gene
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
GB0126782D0 (en) * 2001-11-07 2002-01-02 Medical Res Council Assay
US8124747B2 (en) * 2003-08-29 2012-02-28 Innogenetics HCV clade and prototype sequences thereof
WO2005067643A2 (en) * 2004-01-07 2005-07-28 Third Wave Technologies, Inc. Determination of hepatitis c virus genotype
RU2267496C2 (ru) * 2004-01-15 2006-01-10 Сергей Иванович Черныш Противоопухолевые и антивирусные пептиды
US7968697B2 (en) * 2005-05-25 2011-06-28 Chrontech Pharma Ab Hepatitis C virus non-structural NS3/4A fusion gene
US7465561B2 (en) 2005-06-30 2008-12-16 Roche Molecular Systems, Inc. Probes and methods for hepatitis C virus typing using single probe analysis
BRPI0619748B8 (pt) 2005-12-12 2021-05-25 Ac Immune Sa anticorpo monoclonal, polinucleotídeo, composição, mistura, uso de um anticorpo monoclonal ou uma parte funcional do mesmo, método para preparar uma composição farmacêutica, linhagem celular de hibridoma isolado, método de diagnóstico de uma doença ou condição associada a amilóide em um paciente, método para diagnosticar uma predisposição para uma doença ou condição, método para monitorar doença residual mínima, método para prever a responsividade de um paciente e kits de teste
ME01758B (me) 2006-07-14 2014-09-20 Genentech Inc Humanizirano protutijelo protiv amiloida beta
CA2657681C (en) 2006-07-14 2019-03-19 Ac Immune S.A. Humanized antibodies against beta amyloid protein
CN101563362B (zh) * 2006-08-25 2015-02-11 麦克法兰布奈特医疗研究与公共健康研究所有限公司 重组hcv e2糖蛋白
EP2463389A1 (en) 2006-10-20 2012-06-13 Innogenetics N.V. Methodology for analysis of sequence variations within the HCV NS5B genomic region
EP2527474A1 (en) 2006-10-20 2012-11-28 Innogenetics N.V. Methodology for analysis of sequence variations within the HCV NS3/4A genomic region
CA2670418A1 (en) 2006-11-24 2008-05-29 Ac Immune Sa N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers's
WO2008156622A1 (en) 2007-06-12 2008-12-24 Ac Immune S.A. Humanized antibodies to amyloid beta
TWI453217B (zh) 2007-06-12 2014-09-21 Ac Immune Sa 抗β類澱粉蛋白單株抗體
US20100227314A1 (en) * 2007-08-09 2010-09-09 Dmitry Alexandrovich Gryadunov Method of identification of genotype and subtype of hepatitis c virus on a biological microchip
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
RU2571859C2 (ru) 2007-10-05 2015-12-20 Дженентек, Инк. Применение антитела против амилоида-бета при глазных заболеваниях
WO2009130588A2 (en) * 2008-04-22 2009-10-29 Tripep Ab Immunogen platform
EP2311823A1 (en) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
US20110256064A1 (en) 2010-04-16 2011-10-20 Ac Immune, S.A. Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins
CN102939282B (zh) 2010-04-16 2015-12-02 Ac免疫有限公司 用于治疗与淀粉状蛋白或淀粉状蛋白样蛋白有关的疾病的化合物
US8962241B2 (en) * 2010-07-20 2015-02-24 California Institute Of Technology Triggered molecular geometry based bioimaging probes
WO2012016173A2 (en) 2010-07-30 2012-02-02 Ac Immune S.A. Safe and functional humanized antibodies
KR101988672B1 (ko) 2010-10-07 2019-06-12 에이씨 이뮨 에스.에이. 타우를 인식하는 포스포특이적 항체
US9687447B2 (en) 2010-10-26 2017-06-27 Ac Immune S.A. Method for preparing liposome-based constructs
EP3135689B1 (en) 2011-10-07 2018-12-19 AC Immune S.A. Phosphospecific antibodies recognising tau
KR102132041B1 (ko) 2012-04-05 2020-07-09 에이씨 이뮨 에스.에이. 인간화된 타우 항체
SG11201408161RA (en) 2012-06-08 2015-01-29 Sutro Biopharma Inc Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US9732161B2 (en) 2012-06-26 2017-08-15 Sutro Biopharma, Inc. Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
CN102766701B (zh) * 2012-07-04 2016-05-04 福州泰普生物科学有限公司 丙型肝炎病毒基因分型的试剂盒及方法
EP2890402B1 (en) 2012-08-31 2019-04-17 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
WO2014150877A2 (en) 2013-03-15 2014-09-25 Ac Immune S.A. Anti-tau antibodies and methods of use
RU2667429C2 (ru) * 2013-05-10 2018-09-19 Соединенные Штаты Америки, В Лице Секретаря, Департамента Здравоохранения И Социального Обеспечения Сша Композиции и способы для одновременного обнаружения hcv антигена/антитела
ES2658039T3 (es) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
PT3041864T (pt) 2013-09-05 2021-10-26 Ab2 Bio Sa Proteína de ligação a il-18 (il-18bp) em doenças inflamatórias
EP3055298B1 (en) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
JP7274259B2 (ja) 2015-03-05 2023-05-16 エイビー2 バイオ ソシエテアノニム 炎症性疾患におけるil-18結合タンパク質(il-18bp)および抗体
WO2017218698A1 (en) 2016-06-15 2017-12-21 Sutro Biopharma, Inc. Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
GB201807367D0 (en) 2018-05-04 2018-06-20 Univ Newcastle Biomarker
US20230095053A1 (en) 2020-03-03 2023-03-30 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
US20230173021A1 (en) 2020-05-06 2023-06-08 Ab2 Bio Sa IL-18 Binding Protein (IL-18BP) In Respiratory Diseases
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
WO2023166206A1 (en) 2022-03-04 2023-09-07 Ab2 Bio Sa Il-18 binding protein (il-18bp) in the treatment of vexas
WO2024006563A1 (en) 2022-07-01 2024-01-04 Sutro Biopharma, Inc. Il-12 mutants with reduced toxicity, compositions thereof and methods of using the same
WO2024044780A1 (en) 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990011089A1 (en) 1989-03-17 1990-10-04 Chiron Corporation Nanbv diagnostics and vaccines
US5372928A (en) 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
CA2065287C (en) 1989-09-15 1999-12-21 Tatsuo Miyamura New hcv isolates
HUT56883A (en) 1989-12-18 1991-10-28 Wellcome Found Process for producing virus polypeptides
NZ238681A (en) 1990-06-25 1992-03-26 Univ Osaka Res Found Non-a, non-b hepatitis virus particles and their production
HU227548B1 (en) 1991-05-08 2011-08-29 Novartis Vaccines & Diagnostic Process for production of non-naturally occuring non-hcv-1 nucleic acids, forming a hybridization product, and detecting hcv genotypes
UA40572C2 (uk) * 1991-06-24 2001-08-15 Чірон Корпорейшн Поліпептид, що містить укорочену послідовність вірусу гепатиту с, ізольований епітоп, реагент для імуноаналізу на вірус гепатиту с (варіанти), спосіб виявлення наявності антитіл (варіанти)
EP0532167A3 (en) 1991-08-09 1993-03-31 Immuno Japan Inc. Non-a, non-b hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems
AU679429B2 (en) * 1991-09-13 1997-07-03 Novartis Vaccines And Diagnostics, Inc. Immunoreactive hepatitis C virus polypeptide compositions
DE610436T1 (de) 1991-11-21 1995-08-03 Common Services Agency Detektion des Hepatis-C Virus.
DE69435023T2 (de) * 1993-04-27 2008-09-11 N.V. Innogenetics S.A. Sequenzen der genotype des hepatitis-c-virus sowie ihre verwendung als arzneimittel und diagnostika
JPH06319563A (ja) * 1993-05-13 1994-11-22 Imuno Japan:Kk C型肝炎ウイルス遺伝子、オリゴヌクレオチド、並びにc型 肝炎ウイルス遺伝子型判定方法
US5514539A (en) 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines

Also Published As

Publication number Publication date
US7129337B1 (en) 2006-10-31
EP1076092A3 (en) 2001-03-28
PT804584E (pt) 2002-11-29
BR9509421A (pt) 1997-09-30
AU702436B2 (en) 1999-02-18
ES2176342T5 (es) 2010-02-09
JPH10507643A (ja) 1998-07-28
DE69526973T2 (de) 2003-01-02
WO1996013590A3 (en) 1996-08-15
US6974864B2 (en) 2005-12-13
WO1996013590A2 (en) 1996-05-09
ATE218617T1 (de) 2002-06-15
CA2201703A1 (en) 1996-05-09
JP2005118044A (ja) 2005-05-12
EP0804584B2 (en) 2008-07-09
DE69526973D1 (de) 2002-07-11
AU3844095A (en) 1996-05-23
EP0804584B1 (en) 2002-06-05
DE69526973T3 (de) 2010-01-07
US20020183508A1 (en) 2002-12-05
ES2176342T3 (es) 2002-12-01
EP1076092A2 (en) 2001-02-14
EP0804584A1 (en) 1997-11-05

Similar Documents

Publication Publication Date Title
DK0804584T3 (da) Sekvenser af hepatitis C virus genotype 7 og deres anvendelse som profylaktiske, terapeutiske og diagnostiske midler
FI946066A (fi) Hepatiitti-C viruksen genotyyppien uudet sekvenssit ja niiden käyttö terapeuttisina ja diagnostisina aineina
DE69334357D1 (de) Nachweis und Typisierung das Hepatitis C Virus (HCV) mittels 5'UTR und NS5 Nukleinsäuresequenzen
RU93058449A (ru) Hcv геномные последовательности для диагностических и терапевтических целей
MX9801715A (es) Secuencia novedosa en el extremo 3' del genoma del virus de la hepatitis c, y su uso en diagnostico y en la preparacion de composiciones terapeuticas.
HUP0101719A2 (hu) Javított immundiagnosztikai vizsgálati eljárások redukáló ágensek alkalmazásával
DE69015261D1 (de) Verfahren zum Nachweis des humanen Papillomvirus.
ATE303597T1 (de) Hcv mosaik antigen zusammensetzung
NO20000514D0 (no) Oligonukleotidprimere for effektiv multipleks deteksjon av Hepatitis C-virus (HCV) og human immunmangelvirus (HIV) og metoder for anvendelse derav
DE69106141D1 (de) Non-a non-b sequenzen.
DE60029327D1 (de) Nukleinsaüre- und aminosaürensequenzen von infectious salmon anaemia virus, und deren verwendung als impfstoffe
ATE386122T1 (de) Neue gbv sequenz
IT1270941B (it) Peptidi di hcv e loro usi.
DE3788424T2 (de) Testverfahren des menschlichen b-lymphotropen virus (hblv).